755
Participants
Start Date
January 31, 2007
Primary Completion Date
September 30, 2009
Study Completion Date
September 30, 2009
cabazitaxel (XRP6258) (RPR116258)
25 mg/m\^2 administered by intravenous (IV) route over 1 hour on day 1 of each 21-day cycle
mitoxantrone
12 mg/m\^2 administered by intravenous (IV) route over 15-30 minutes on day 1 of each 21-day cycle
prednisone
10 mg daily administered by oral route
sanofi-aventis US, Bridgewater
sanofi-aventis Argentina, Buenos Aires
sanofi-aventis Belgium, Diegem
sanofi-aventis Brazil, São Paulo
sanofi-aventis Canada, Laval
sanofi-aventis Chile, Santiago
sanofi-aventis Czech Republic, Prague
sanofi-aventis Denmark, Hørsholm
sanofi-aventis Finland, Helsinki
sanofi-aventis France, Paris
sanofi-aventis Germany, Berlin
Sanofi-Aventis Hungaria, Budapest
sanofi-aventis India, Mumbai
sanofi-aventis Italy, Milan
sanofi-aventis Mexico, México
sanofi-aventis Netherlands, Gouda
sanofi-aventis Russia, Moscow
sanofi-aventis Singapore, Singapore
sanofi-aventis Slovakia, Bratislava
sanofi-aventis South Africa, Midrand
sanofi-aventis South Korea, Seoul
sanofi-aventis Spain, Barcelona
sanofi-aventis Sweden, Bromma
sanofi-aventis Taiwan, Taipei
sanofi-aventis Turkey, Istanbul
sanofi-aventis UK, Guildford
Lead Sponsor
Sanofi
INDUSTRY